These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17627534)

  • 41. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Changing Epidemiology of Meningococcal Disease.
    Cohn A; MacNeil J
    Infect Dis Clin North Am; 2015 Dec; 29(4):667-77. PubMed ID: 26610420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An evaluation of emerging vaccines for childhood meningococcal disease.
    Choudhuri D; Huda T; Theodoratou E; Nair H; Zgaga L; Falconer R; Luksic I; Johnson HL; Zhang JS; El Arifeen S; Nelson CB; Borrow R; Campbell H; Rudan I
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S29. PubMed ID: 21501447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.
    Gasparini R; Panatto D; Bragazzi NL; Lai PL; Bechini A; Levi M; Durando P; Amicizia D
    J Immunol Res; 2015; 2015():189153. PubMed ID: 26351643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt.
    Norheim G; Tunheim G; Næss LM; Kristiansen PA; Caugant DA; Rosenqvist E
    Scand J Immunol; 2012 Aug; 76(2):99-107. PubMed ID: 22537024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.
    Sadarangani M; Hoe JC; Callaghan MJ; Jones C; Chan H; Makepeace K; Daniels-Treffandier H; Deadman ME; Bayliss C; Feavers I; van der Ley P; Pollard AJ
    PLoS One; 2012; 7(12):e51045. PubMed ID: 23251421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MenHibrix: a new combination meningococcal vaccine for infants and toddlers.
    Hale SF; Camaione L; Lomaestro BM
    Ann Pharmacother; 2014 Mar; 48(3):404-11. PubMed ID: 24353263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil.
    Bricks LF
    Rev Hosp Clin Fac Med Sao Paulo; 2003; 58(4):231-40. PubMed ID: 14534678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meningococcal polysaccharide-protein conjugate vaccines.
    Snape MD; Pollard AJ
    Lancet Infect Dis; 2005 Jan; 5(1):21-30. PubMed ID: 15620558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine Failure After Meningococcal C Conjugate Vaccine May Be Linked to Decline of Bactericidal Titers and Absence of Herd Immunity.
    Matar R; Hong E; Levy C; Guillot M; Cohen R; Taha MK; Madhi F
    Pediatr Infect Dis J; 2015 Oct; 34(10):1142-3. PubMed ID: 26367811
    [No Abstract]   [Full Text] [Related]  

  • 53. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
    Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
    PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations.
    Baker CJ
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S29-37. PubMed ID: 27449147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A vaccine against meningitis in Africa.
    Lancet Infect Dis; 2011 Jan; 11(1):1. PubMed ID: 21183138
    [No Abstract]   [Full Text] [Related]  

  • 56. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
    Villena R; Safadi MAP; Valenzuela MT; Torres JP; Finn A; O'Ryan M
    Hum Vaccin Immunother; 2018 May; 14(5):1042-1057. PubMed ID: 29667483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
    Pérez-Trallero E; Esnal O; Marimón JM
    PLoS One; 2014; 9(12):e116024. PubMed ID: 25541709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.
    Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM
    J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expanding prevention of invasive meningococcal disease.
    Pelton SI; Gilmet GP
    Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.